PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
153.33%
Revenue growth of 153.33% vs. zero growth in Healthcare. Walter Schloss might still want to see if it can translate into profits.
73.30%
Gross profit growth of 73.30% while Healthcare median is zero. Walter Schloss might see a slight advantage that could be built upon.
-15.23%
Negative EBIT growth while Healthcare median is -0.14%. Seth Klarman would check if external or internal factors caused the decline.
-15.23%
Negative operating income growth while Healthcare median is -1.52%. Seth Klarman would check if structural or cyclical issues are at play.
-9.33%
Negative net income growth while Healthcare median is 0.00%. Seth Klarman would investigate factors dragging net income down.
-5.41%
Negative EPS growth while Healthcare median is 0.00%. Seth Klarman would explore whether share dilution or profit declines are to blame.
-8.33%
Negative diluted EPS growth while Healthcare median is 0.00%. Seth Klarman would look for the cause: weakened profitability or heavier share issuance.
2.98%
Share growth above Healthcare median by more than 2x. Jim Chanos would suspect over-dilution or repeated equity raises.
2.03%
Diluted share growth above 2x Healthcare median. Jim Chanos would suspect undue issuance or heavy employee stock compensation.
No Data
No Data available this quarter, please select a different quarter.
-36.10%
Negative OCF growth while Healthcare median is 0.00%. Seth Klarman would ask if accounting or macro issues hamper the firm specifically.
-34.66%
Negative FCF growth while Healthcare median is 0.00%. Seth Klarman would see if others in the industry are still generating positive expansions in free cash.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
95.84%
OCF/share CAGR of 95.84% while Healthcare median is zero. Walter Schloss might see a modest edge that can add up if momentum improves.
71.82%
OCF/share CAGR of 71.82% while Healthcare median is zero. Walter Schloss might see a slight advantage that can compound if momentum builds.
66.77%
3Y OCF/share growth of 66.77% while Healthcare median is zero. Walter Schloss might see a modest advantage that could compound if momentum holds.
96.67%
Net income/share CAGR of 96.67% while Healthcare median is zero. Walter Schloss might see a marginal edge that can grow if the firm invests wisely.
77.76%
Net income/share CAGR of 77.76% while Healthcare median is zero. Walter Schloss might see a modest advantage that can expand mid-term.
53.48%
3Y net income/share CAGR of 53.48% while Healthcare median is zero. Walter Schloss might see a small advantage that can be scaled further.
61.16%
Equity/share CAGR exceeding 1.5x Healthcare median of 34.10% over 10 years. Joel Greenblatt would see if a high ROE underlies this compounding advantage.
-44.17%
Negative 5Y equity/share growth while Healthcare median is 11.10%. Seth Klarman suspects firm-specific weaknesses if peers grow equity mid-term.
152.11%
3Y equity/share CAGR > 1.5x Healthcare median of 11.31%. Joel Greenblatt sees strong short-term returns on equity fueling net worth growth.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Dividend reductions while Healthcare median grows. Seth Klarman sees a near-term disadvantage if peers maintain or raise payouts.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-2.25%
Assets shrink while Healthcare median grows. Seth Klarman might see a strategic refocus or potential missed expansion if demand is present.
-9.40%
Negative BV/share change while Healthcare median is -0.39%. Seth Klarman sees a firm-specific weakness if peers accumulate net worth.
-0.77%
Debt is shrinking while Healthcare median is rising. Seth Klarman might see an advantage if growth remains possible.
8.30%
R&D growth of 8.30% while Healthcare median is zero. Walter Schloss wonders if a slight increase yields a meaningful competitive edge.
28.80%
SG&A growth far above Healthcare median. Jim Chanos sees potential red flags in cost management or diminishing returns on spending.